Table 1.
Cost and effectiveness with baseline parameters
| Health states | Av. Total | |||||
|---|---|---|---|---|---|---|
| Non-compliant | Primary closure | No primary closure | Final closure | No final closure | ||
| Probability of health states | ||||||
| WHO EMRO protocola | 0.39 | 0.48 | 0.03 | 0.08 | 0.03 | 1.00 |
| Group I | 0.39 | 0.48 | 0.03 | 0.08 | 0.03 | 1.00 |
| Group II | 0.28 | 0.62 | 0.01 | 0.06 | 0.03 | 1.00 |
| Group III | 0.26 | 0.51 | 0.01 | 0.06 | 0.16 | 1.00 |
| Direct medical cost | ||||||
| Group I (US$) | 0.87 | 3.48 | 3.48 | 4.93 | 4.93 | 2.63 |
| Group II (US$) | 0.81 | 3.26 | 28.31 | 6.26 | 23.40 | 3.58 |
| Group III (US$) | 1.05 | 4.21 | 28.14 | 8.02 | 24.53 | 7.09 |
| Injections/dressings | ||||||
| WHO EMROa (N =) | 2 | 8 | 8 | 13 | 13 | 6 |
| Group I (N =) | 3 | 12 | 12 | 17 | 17 | 9 |
| Group II (N =) | 3 | 11 | 101 | 21 | 72 | 12 |
| Group III (N =) | 4 | 15 | 101 | 28 | 73 | 23 |
| Drug cost | ||||||
| WHO EMROa (US$) | 1.32 | 5.28 | 5.28 | 8.58 | 8.58 | 4.11 |
| Group I (US$) | 0.40 | 1.58 | 1.58 | 2.24 | 2.24 | 1.20 |
| Group II (US$) | 0.47 | 1.87 | 17.17 | 3.57 | 12.24 | 2.03 |
| Group III (US$) | 0.64 | 2.55 | 17.17 | 4.76 | 12.41 | 3.90 |
| Direct non-medical cost | ||||||
| Group I (US$) | 1.36 | 7.70 | 7.70 | 9.97 | 9.97 | 5.50 |
| Group II (US$) | 1.88 | 10.26 | 69.22 | 17.57 | 49.59 | 10.05 |
| Group III (US$) | 2.23 | 11.29 | 60.12 | 19.35 | 43.47 | 15.02 |
| Indirect cost | ||||||
| Group I (US$) | 5.82 | 1.32 | 5.82 | 1.61 | 5.29 | 3.31 |
| Group II (US$) | 5.82 | 0.63 | 5.82 | 1.64 | 4.80 | 2.32 |
| Group III (US$) | 5.82 | 0.86 | 5.82 | 1.61 | 5.07 | 2.90 |
| Total average cost | ||||||
| Group I (US$) | 8.05 | 12.50 | 17.00 | 16.51 | 20.19 | 11.43 |
| Group II (US$) | 8.51 | 14.15 | 103.35 | 25.47 | 77.79 | 15.91 |
| Group III (US$) | 9.10 | 16.36 | 94.08 | 28.98 | 73.07 | 24.97 |
| Wound free days | ||||||
| Group I (WFD) | 0 | 234 | 0 | 207 | 0 | 129 |
| Group II (WFD) | 0 | 270 | 0 | 167 | 0 | 177 |
| Group III (WFD) | 0 | 258 | 0 | 233 | 0 | 147 |
| ICER | ||||||
| Group I (US$/WFD) | N.A. | 0.00 | N.A. | 0.00 | N.A. | 0.00 |
| Group II (US$/WFD) | N.A. | 0.05 | N.A. | −0.22 | N.A. | 0.09 |
| Group III (US$/WFD) | N.A. | 0.16 | N.A. | 0.48 | N.A. | 0.77 |
| NMB (WTP = 1.92) | ||||||
| Group I (US$) | −8 | 437 | −17 | 381 | −20 | 236 |
| Group II (US$) | −9 | 504 | − 103 | 295 | − 78 | 324 |
| Group III (US$) | −9 | 479 | −94 | 418 | −73 | 257 |
All costs in 2013 US$
a WHO EMRO protocol is defined as 1 to 5 ml IL SSG, twice weekly for three to 4 weeks [4]. The probability of health states of Group I was also assumed for the IL SSG WHO EMRO protocol, as a best guess. We assumed a mean IL SSG dosage of 3 ml per injection and 5 additional injections for final closure based on the IL SSG re-ulceration time found in Stahl et al. [3]